 Connection
Myron Levin to Cohort Studies
This is a "connection" page, showing publications Myron Levin has written about Cohort Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.181 |
|
|
|
-
Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, Levin MJ. Incidence of herpes zoster in patients with altered immune function. Infection. 2014 Apr; 42(2):325-34.
Score: 0.056
-
Ku JH, Levin MJ, Luo Y, Florea A, Lin IC, Tian Y, Tseng HF. Risk of Severe Coronavirus Disease 2019 Disease in Individuals With Down Syndrome: A Matched Cohort Study From a Large, Integrated Health Care System. J Infect Dis. 2022 09 13; 226(5):757-765.
Score: 0.026
-
Hawkins KL, Gordon KS, Levin MJ, Weinberg A, Battaglia C, Rodriguez-Barradas MC, Brown ST, Rimland D, Justice A, Tate J, Erlandson KM. Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr. 2018 12 01; 79(4):527-533.
Score: 0.020
-
Weinberg A, Muresan P, Richardson K, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ. Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women. AIDS Res Hum Retroviruses. 2015 Nov; 31(11):1170-7.
Score: 0.016
-
Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis. 1992 Aug; 166(2):253-9.
Score: 0.013
-
Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012 Nov 15; 55(10):1320-8.
Score: 0.013
-
Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011 Dec; 7(12):1343-58.
Score: 0.012
-
Irwin MR, Levin MJ, Carrillo C, Olmstead R, Lucko A, Lang N, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Johnson G, Oxman MN. Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain Behav Immun. 2011 May; 25(4):759-66.
Score: 0.012
-
Schuval S, Lindsey JC, Stapleton JT, Van Dyke RB, Palumbo P, Mofenson LM, Oleske JM, Cervia J, Kovacs A, Dankner WN, Smith E, Nowak B, Ciupak G, Webb N, Eagle M, Smith D, Hennessey R, Goodman-Kerkau M, Klinzman D, Hess G, Zdunek D, Levin MJ. GB virus C infection in children with perinatal human immunodeficiency virus infection. Pediatr Infect Dis J. 2005 May; 24(5):417-22.
Score: 0.008
-
Starr SE, McFarland EJ, Muresan P, Fenton T, Pitt J, Douglas SD, Deveikis A, Levin MJ, Rathore MH. Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children. AIDS. 2003 Oct 17; 17(15):2181-9.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|